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Department of Medicine, University of Cambridge, Cambridge, UKPopulations in developed countries continue to grow older and tion have the lowest future health costs, so the solvency of mod-
an understanding of the ageing process to allow healthy ageing
carries important medical implications. Older individuals are
more susceptible to most acquired liver disorders and more vul-
nerable to the consequences of liver disease. Accordingly, age is a
critical determinant of outcome for hepatitis C virus infection and
liver transplantation. In this review we describe changes in the
ageing liver and discuss mechanisms of senescence at the cellular
level. In particular, we focus on mechanisms by which inﬂamma-
tion, oxidative stress, and oncogenic stress accelerate cellular
senescence. In the setting of chronic hepatic injury and inﬂam-
mation, cellular senescence functions as an essential stress-
response mechanism to limit the proliferation of damaged cells
and reduce the risk of malignancy, but this beneﬁt is achieved
at the expense of senescence-related organ dysfunction. The dual
role of cell senescence in chronic liver disease will make this an
intriguing but challenging area for future clinical interventions.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
According to Greek mythology, the Goddess Eos asked Zeus to
grant immortality to the Trojan Tithonus, her mortal lover. But
Eos had forgotten to ask for eternal youth so Tithonus received
the ‘‘gift” of immortality and continued to age, withering beyond
recognition and begging eternally for death (Fig. 1). In similar
fashion, modern medicine, combined with improved sanitation
and better nutrition, has increased the life expectancy of individ-
uals in the developed world, but this has not been matched by
progress in alleviating the ill health associated with increased
age.
An increasing proportion of the healthcare budget is devoted
to the growing geriatric population, so it is essential to under-
stand the molecular basis of ageing and identify possible avenues
for therapeutic intervention [1]. Clearly, patients of the same age
can vary in terms of physiological reserve and susceptibility to
disease in the absence of co-morbidity. The healthiest 70-year
olds with the longest life expectancy within the ageing popula-Journal of Hepatology 20
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but extending disease free survival.
Studies of healthy human ageing have relied largely on the
study of healthy elderly individuals or by studying younger indi-
viduals afﬂicted with one of the Progeria syndromes associated
with accelerated and premature ageing [2,3]. However, both
approaches are affected by methodological problems. The former,
by ‘survivor bias’ [4], i.e. those individuals who have survived to
old age may show retarded features of biological ageing com-
pared to those who have died; the latter, by a lack of understand-
ing of the underlying pathophysiology and its relevance to
normal human ageing.
The incidence of liver disease increases with age while the
ability to withstand a hepatic insult falls with each decade. The
cellular and sub-cellular changes that underlie this predisposition
are the subject of much scrutiny. Interest in the role of ageing
within the sphere of hepatology has increased, especially with
the recent recognition of the critical importance of age in deter-
mining the clinical outcome in chronic hepatitis C virus infection
[5] and the inﬂuence of donor age on graft survival after liver
transplantation [6]. Furthermore, liver-related death in older per-
sons is increased substantially when compared to younger indi-
viduals with the same condition [7].
There is irrefutable evidence that the ageing process occurs at
the cellular level and that such changes can be induced ‘prema-
turely’ by inﬂammation. Cellular senescence is an important
stress related response to injury that induces stable cell-cycle
arrest with important implications for survival of the cell, organ,
and organism by preventing replication of a cell in which the
integrity of DNA has been compromised. The award of the 2009
Nobel prize for Medicine to Blackburn, Greider, and Szostak for
research in telomere biology has brought the ﬁeld of ageing
research to the fore.Hepatocyte changes with age
Hepatocyte structure changes with age. The volume of hepato-
cytes increases with development and maturation but declines
with senescence [8,9]. The relative volumes of hepatocyte organ-
elles also change during ageing.
The most common change on diagnostic liver biopsy speci-
mens is age-related cytoplasmic accumulation of highly oxidised
insoluble proteins, known as lipofuscin (Fig. 2A) [10,11]. Lipofus-
cin can be seen on H & E staining, are PAS diastase resistant and
do not stain with Chromotrope Aniline Blue (Fig. 2B and C). These10 vol. 53 j 950–961
Fig. 1. Eos and Tithonus. The Goddess Eos abducting the Trojan Tithonus in his
youth portrayed traditionally holding a lyre.
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relate to chronic oxidative stress and a failure to degrade dam-
aged and denatured proteins [11]. Increasing evidence suggests
that lipofuscin interferes with cellular pathways due to its ability
to trap metallic cations and facilitate further free radical forma-
tion [12].
Other sub-cellular hepatocyte changes with age are less well
described and most data are derived from animal studies. There
is a marked decline in smooth endoplasmic reticulum surface
area with age [9,13] which correlates with decreased hepaticFig. 2. Age-related changes seen on liver biopsy specimens include accumu-
lation of lipofuscin (A–C) and large cell change (D). Liver biopsy specimen
taken from a 72 year-old male with NAFLD stained with (A) haematoxylin and
Eosin (H&E), diastase periodic-acid Schiff (dPAS) (B) and Chromotrope Aniline
Blue (CAB) stain demonstrating intra-cytoplasmic granules of lipofuscin (arrow
heads) adjacent to an hepatic venule (v) conﬁrmed as dPAS resistant (B) but
negative on the CAB stain (C). (D) Large cell change from the same biopsy
specimen (arrow). Images were taken at 40 magniﬁcation, courtesy of Dr. Susan
Davies.
Journal of Hepatology 201microsomal protein concentrations and enzymatic activity such
as glucose-6-phosphatase [13]. Recent data suggest there is an
age-related decline in chaperone-mediated autophagy, the cellu-
lar pathway leading to degradation of molecules and sub-cellular
organelles. In a mouse model associated with age-related decline
in liver function, restoration of autophagy was associated with
maintenance of liver function [14].
There are also data suggesting a change in hepatocyte nuclear
morphology with increasing age. It is known that there is
increased variation in nuclear size [15], associated with an
increasing incidence of polyploidy of hepatocytes [16]. After the
age of 85, around 27% of human hepatocytes demonstrate poly-
ploidy compared to around 6% for individuals in their twenties
[17].Changes in the response of the liver to injury with age
One of the most important age-related changes in liver function
is the demonstration in animal models of a signiﬁcant decrease
in regenerative capacity of the liver [18–20]. In rat studies utilis-
ing the partial hepatectomy model, complete hepatic restoration
occurs in older animals, but at a slower rate than in younger ani-
mals [21]. Liver regeneration in both young and old animals was
complete by day 7 after 70% hepatectomy, but at day 1 younger
animals had signiﬁcantly increased liver mass and increased
intrahepatic mitotic activity [22].
Newer evidence indicates an active age-related change in
the regulation of hepatocyte proliferation. Iakova et al. demon-
strated that repression of hepatocyte proliferation after hemi-
hepatectomy was switched actively from one intracellular
pathway to another in older rat hepatocytes [23]. C/EBPa
represses hepatocyte proliferation through inhibition of cyclin
dependent kinases (CDK), but after hemi-hepatectomy it under-
goes down-regulation to allow liver reconstitution [24]. Iakova
et al. demonstrated that aged rat hepatocytes expressed higher
levels of the chromatin remodelling protein Brm. Interaction of
C/EBPa with Brm led to the formation of high molecular
weight complexes leading to switch of proliferative repression
from CDKs to E2F-promoted genes [23]. In their model the
repression switch was associated with impaired hepatocyte
proliferation after hemi-hepatectomy.
Clinical outcome in human acute liver injury is also in part
dependent upon the potential for hepatic regeneration. Older
people have a higher incidence of acute liver failure and a higher
mortality with acute hepatitis A [25,26]. In a cohort of patients
with acute liver failure secondary to viral hepatitis, age was an
independent predictor of a poor outcome with those over ﬁfty
years old faring worst [27].Ageing and chronic liver diseases
Increasing age has now been recognised as a signiﬁcant correlate
of a poor outcome in a number of chronic liver disorders (Table 1).
Perhaps the best studied is chronic HCV infection. Wong et al. and
Poynard et al. were among the ﬁrst to demonstrate that age at
infection was a major risk factor for subsequent ﬁbrosis progres-
sion [5,28] and further, that the rate of ﬁbrosis progression accel-
erated with increasing age [29]. Other groups have conﬁrmed










Table 1. Recent studies linking age and clinical outcome in a variety of liver diseases. HCV, hepatitis C virus; HBV, hepatitis B virus; PBC, primary biliary cirrhosis;
AIH, autoimmune hepatitis; NAFLD, non-alcoholic fatty liver disease; A1-AT, alpha-1 anti-trypsin deﬁciency.
Disease Authors Year Summary Ref
HCV Poynard et al 1997 Age at infection older than 40 years associated with accelerated fibrosis progression  [5] 
Pradat et al 2006 Age at infection above 37 years independently associated with faster fibrosis progression  [31] 
Ryder et al 2004 Age at biopsy independently associated with fibrosis progression in paired biopsy study  [32] 
Minola et al 2002 Increased age at infection independently associated with risk of development of cirrhosis  [33] 
Wright et al 2003 Increased age at infection and biopsy independently associated with faster fibrosis progression  [34] 
Poynard et al 2001 Increasing age was associated with increased rates of fibrosis progression [29] 
HBV Poynard et al 2005 Increasing age independently associated with presence of bridging fibrosis [144] 
Papatheodoridis et al 2005 Increasing age associated with accelerated fibrosis progression in HBeAg –ve HBV  [145] 
Chu et al 2009 HBV reactivation and development of cirrhosis associated with increased age [146] 
PBC Goudie et al 1989 Increasing age associated with liver-related mortality in PBC [35] 
Chan et al 2005 Increasing age associated with death in PBC [147] 
Prince et al 2002 Increasing age independently associated with death in PBC [148] 
Alcohol Forrest et al 2005 Increased age independently associated with mortality in alcoholic hepatitis [36] 
Louvet et al 2007 Increased age independently associated with mortality in alcoholic hepatitis [149] 
Dominguez et al 2008 Increased age independently associated with mortality in alcoholic hepatitis [150] 
AIH Floreani et al 2006 Higher rate of acute presentation  and higher stage of fibrosis in aged patients [151] 
Al-Chalabi et al 2006 Increased rate of decompensation at presentation in older subjects, but increased rate 
[152]
Czaja et al 2006 Increased rate of cirrhosis at presentation [153]
NAFLD Ratziu et al 2000 Age >50 independently associated with presence of septal fibrosis on biopsy [37]
Angulo et al 1999 Increased age independently associated with the presence of bridging fibrosis or cirrhosis [38]
A1-AT  Dawkins et al 2003 Increasing age independently predicted respiratory and all-cause mortality [154]
Haemochromatosis Olynyk et al 2005 Increasing age predicted presence of severe fibrosis [155]
Stickel et al 2005 Increasing age independently predicted faster progression to cirrhosis [156]
Budd-Chiari Garcia-Pagan et al 2008 Post-TIPSS, increasing age predicted lower transplant-free survival [157]
Zeitoun et al 1999 Age at diagnosis independently predicted outcome [158]
of response to steroids
Reviewhave accelerated ﬁbrosis compared to younger individuals [30–
34].
Studies of other liver diseases have demonstrated similar ﬁnd-
ings. Age is an independent risk factor for poor outcome in pri-
mary biliary cirrhosis (PBC) in addition to the presence of
portal hypertension and impaired liver function [35]. Similarly,
age independent of bilirubin, prothrombin time, and renal func-
tion predicted outcome in patients with alcoholic hepatitis [36].
There is some evidence that age may inﬂuence disease pro-
gression in non-alcoholic fatty liver disease (NAFLD). Studies
from France and USA have shown that increasing age, increasing
body mass index, and type-2 diabetes were associated indepen-
dently with cirrhosis in patients with NAFLD [37,38]. Being older
than 50 years gave an odds ratio of 14 for the presence of at least
severe ﬁbrosis [37].
Work by Wali et al. [39] and Berenguer et al. [40] indicate an
association between advancing allograft donor age and more
rapid histologic progression after HCV graft infection. If the liver
donor was younger than 40 years, the median interval to post-
transplant cirrhosis was 10 years compared to only 2.2 years
when the donor was aged 50 years or more [39]. Berenguer
et al. studied 522 patients undergoing liver transplantation
between 1991 and 2000, including 283 (54%) infected with
HCV. Patient survival was lower in HCV positive recipients and
they suggest that the increasing age of donor organs was contrib-









Fig. 3. Causes and consequences of cellular senescence. Cellular senescence
can be caused by a number of cellular stresses including telomere dysfunction.
Other causes include oxidative stress, non-telomeric DNA damage, and oncogenic
activation. Cellular senescence is characterised by cell-cycle arrest, resistance to
apoptosis, epigenetic changes including formation of senescence-associated
heterochromatic foci, and the senescence-associated secretory phenotype.Mechanisms of ageing and senescence in the liver
There has been considerable progress in elucidating mechanisms
that regulate the capacity for cell division and regeneration in the
context of ageing. Senescence is a stress-responsive programme
limiting the proliferation of damaged cells and leading to stable
cell-cycle arrest [41]. It was initially identiﬁed as replication-952 Journal of Hepatology 201induced senescence of cultured human ﬁbroblasts by Hayﬂick
et al. [42]. However, it can develop in many cell types in response
to a range of cellular stressors such as telomere dysfunction, oxi-
dative, and oncogenic stress (Fig. 3) [43]. This review focuses on
the evidence for replicative senescence and telomere signalling in
the pathogenesis of liver disease and hepatic neoplasia.Telomeres and DNA damage signalling
Substantial attention has focussed on the telomere/telomerase











Fig. 5. Structure of mammalian telomeres. (A) The G-rich 30 single-stranded
overhang inserts into the upstream double-stranded telomeric DNA to form a
protective t-loop conﬁguration at the end of chromosomes. (B) Peri-telomeric
shelterin complex contains six proteins in mammals: TRF1, TRF2, TIN2, RAP1,
TPP1, and POT1. POT1 prevents the generation of a single-stranded DNA damage
response by binding to the 30 overhanging strand. Adapted from Cesare and
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repeating hexanucleotide sequences which, with their associated
protein complexes, function to protect chromosomes against
chromosomal end-end fusion and non-reciprocal translocations.
Telomere length can be measured by a number of experimen-
tal methodologies (Fig. 4). Enzymatic digestion of telomere DNA
and Southern blotting remains the standard but may soon be
superseded by PCR-based assays; these methods give absolute
telomere lengths. However, telomere lengths of speciﬁc cells or
cellular sub-populations are difﬁcult without prior cell sorting.
In situ hybridisation assays can be performed on cells either in
suspension as a ﬂow-based assay (Fig. 4A) or on tissues
(Fig. 4D). This has the advantage of allowing telomere analysis
of single cells or speciﬁc cell populations. However, the telomere
length generated is measured as ﬂuorescence intensity relative to
an internal control, not an absolute length. An estimate of abso-
lute length can be achieved through reference to a paired sample
analysed by Southern blotting.
Telomere structure includes a double-strand component of
10–12 kb of TTAGGG repeats and a 30 single-strand overhang of
several hundred nucleotides. The 30 overhang inserts in the
upstream double strand telomere sequence to form a protective
T-loop [45]; this protects the telomere from developing a DNA
damage response (Fig. 5A).
The shelterin complex of peri-telomere proteins, including
telomere repeat-binding factors 1 and 2 (TRF1 and TRF2)
(Fig. 5B), binds to the double-stranded telomere and is crucial
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Fig. 4. Telomere analysis by in situ hybridisation. (A–C) Examples of experi-
mental methodologies demonstrating telomeres in human CD4+ lymphocytes by
ﬂow cytometric FISH, and (D) hepatocytes by quantitative FISH. Fresh human
PBMCs are stained for CD4 and then a ﬂuorochrome-labelled telomere consensus
sequence is hybridised. Cells are then analysed in a ﬂow-cytometer, gating on live
lymphocytes (A), CD4+ lymphocytes (B), and then telomere length can be inferred
from the mean ﬂuorescence intensity (C). Parafﬁn-embedded liver biopsy tissue
from a subject with NAFLD was stained with the hepatocyte-speciﬁc antibody
Hep Par-1 (Green), nuclear stain DAPI (blue), and ﬂuorochrome-labelled telomere
consensus sequence (red) allowing study of telomeres in single cells or cellular
populations. (Image courtesy of Dr. Aloysius Aravinthan).
Reddel, 2010 [136].
Journal of Hepatology 201abundant at the telomere but not elsewhere in nuclear DNA,
due to the high-speciﬁcity binding sites for telomere repeats in
TRF1 and 2, [46]. The importance of TRF2 was demonstrated by
van Steensel et al. in a ﬁbrosarcoma cell line [47]. Expression of
a dominant negative allele of TRF2 led to end-to-end chromo-
somal fusions despite the presence of adequate telomere length.
Protector of telomeres-1 (POT1) binds to the single-strand DNA
overhang to prevent the development of a single-strand DNA
damage response and functions with TPP1 to facilitate binding
of telomerase [48].
In the absence of compensatory mechanisms, telomere DNA
shortens with each division, reﬂecting incomplete synthesis of
telomere termini during chromosomal replication [4]. With
repeated cell division a point of critical telomere shortening is
reached and a growth arrest signal is expressed, preventing fur-
ther cell division. Short or dysfunctional telomeres cannot protect
chromosomal integrity from progressive attrition or uncapping
associated with loss of shelterin complex components such as
TRF2 [49].
Short telomeres are detected as double-strand DNA breaks by
the MRN complex of proteins, including MRE11, NBS1, and
RAD50 (Fig. 6) [49,50]. With progressive loss of telomeres, there
is a commensurate loss of inhibitors of DNA damage response ele-
ments suchasTRF2 [50]. Lossof this inhibition leads to recruitment
of the PI3-kinases ATM and ATR, phosphorylation of Histone 2A at
serine 139 (c-H2AX) and stabilisation of p53 [4,50,51], and p21
[52,53]; the involvement of p16 in the induction of senescence is
controversial [43,53]. The mechanisms that determine whether a
cell undergoes senescence or apoptosis in response to telomere
dysfunction-induced-DNA damage response are not understood.
Replicative senescence is characterised in vitro by growth arrest,0 vol. 53 j 950–961 953
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Fig. 6. Short telomeres generate a double strand break (DSB) DNA damage
response. Progressive telomere shortening is signalled to ATM/ATR by the MRN
complex leading to phosphorylation of Histone 2 (H2) at serine 139 to form
c-H2AX (B). Generation of c-H2AX leads to a positive feedback loop-inducing
phosphorylation of further ATM/ATR. c-H2AX also allows binding of other factors
in the DSB response pathway including the mediator of DNA damage checkpoint
protein 1 (MDC1) and p53 binding protein-1 (53BP1) [50] (C). Activation of ATM/
ATR leads to downstream signalling through phosphorylation of the checkpoint
kinases CHK1 and CHK2 leading to activation of p53 and arrest of further mitosis.
Reviewan inability to respond to external mitogens, and altered cell mor-
phology. Short telomeres detected duringDNA replication atmito-
tic S-phase may induce apoptosis [54].
Under certain circumstances telomeres can form a four-strand
quadruplex rather than T-loop structure which prevents access of
telomerase to the 30 overhanging strand. This is associated with
accelerated telomere attrition leading to senescence [55].
Accelerated telomere shortening has been demonstrated in
conditions associated with inﬂammation and accelerated cell
turnover [56], leading to the concern that continued hepatocyte
turnover in chronic inﬂammatory liver disease may lead to telo-
mere-mediated loss of replicative ability and a reduced potential
for regeneration. Further, known risk factors for ill-health (and
which play a part in chronic liver disease) such as obesity and
smoking are associated with accelerated loss of telomere DNA
[57,58].
Several studies have investigated telomere length and down-
stream telomere signalling in healthy hepatocytes with increas-
ing age. Wang et al. studied mice of increasing age and
demonstrated in vivo accumulation of c-H2AX foci within hepa-
tocytes [59]. However, mice have telomeres that are signiﬁcantly
longer than those in humans and there was no signiﬁcant co-
localisation between c-H2AX foci and telomeres in gut epithe-
lium. This suggests that the DNA damage response may rely more
on accumulation of DNA damage distant to the telomere with
advancing age. Aikata et al. demonstrated that telomere length
in human liver, without reference to cell type, measured by
restriction fragment length declined with age by around 120 base954 Journal of Hepatology 201pairs per year, but that no normal liver sample had telomere
lengths shorter than 5 kb [60]. Other groups have demonstrated
a decline in hepatic telomeres from 9.7 kb at age 20 to 8.1 kb at
age 60, a decline of 40 bp per year [61].Telomerase
Telomerase is a reverse transcriptase consisting of enzymatic
(TERT), RNA template (TERC) and several other protein compo-
nents including heat-shock protein 90 (hsp90) and dyskerin
[62]. Telomerase can maintain telomere length by adding
TTAGGG repeats, but its expression is controlled in differentiated
[63,64] and stem-cell populations [65]. In stem-cell populations
over-expression of telomerase activity led to increased prolifera-
tion of epidermal stem cells and differentiation of their progeny
[65]. Ectopic expression of telomerase in retinal pigment epithe-
lial cells and ﬁbroblasts led to lengthening of telomeres, contin-
ued cell division, and extension of in vitro lifespan [66].
Re-expression in non-stem-cell populations in healthy life is
unusual, but telomerase is expressed in around 80% of human
carcinomas, including hepatocellular carcinoma [67].
A recent genomewide-association study looking at the natural
variability of telomere length in healthy human populations has
identiﬁed single-nucleotide polymorphisms on chromosome 3q,
an area coding TERC, which was associated with shorter telo-
meres. Each copy of the identiﬁed allele was associated with telo-
mere shortening equivalent to around 4-years natural ageing [68].
Recent evidence has suggested that telomerase may have
a role in several cellular pathways beyond its known role in
elongation of telomeres and replicative ageing. Regulation of
apoptosis, gene expression, and chromatin structure during the
cell-cycle has been ascribed to telomerase activity [69].
Genetic evidence for a role of telomere dysfunction in human
ageing comes from the discovery that germ-line mutations of the
telomerase complex component dyskerin cause the Progeroid
syndrome Dyskeratosis Congenita (DKC) [3,70]. Patients with
DKC are at increased risk of malignancies, pulmonary ﬁbrosis,
and cirrhosis. However, unchecked telomere shortening leads
eventually to bone marrow failure, which is fatal often in the sec-
ond or third decade.
In the ﬁeld of liver disease, there is a growing body of evi-
dence for the role of hepatocyte telomere shortening in relation
to clinical outcome. Reduction in whole liver or hepatocyte telo-
meres occurs with normal ageing and may give an indication of
residual proliferative potential [60,71]. Aikata et al. demonstrated
a progressive decline in telomere length in whole liver biopsy
samples with increasing age in both healthy subjects and subjects
with chronic liver disease [60]. Takubo et al. demonstrated that
telomere length in whole liver biopsy specimens declines at a
similar rate to that in highly proliferative tissues such as digestive
tract mucosa [71].Telomeres in chronic liver disease
Short human telomeres have been linked to the subsequent onset
of disease and death [72] in healthy older persons. Both Kitada
et al. and Urabe et al. showed that subjects with chronic viral
hepatitis had shorter hepatic telomeres than healthy controls
and that increasing ﬁbrosis was associated with shorter telomere0 vol. 53 j 950–961
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lengths [73,74]. However, their methodology was based on
homogenates of liver tissue with restriction fragment length
analysis, which precluded identiﬁcation of the particular liver
cells that underwent telomere shortening. Wiemann et al. dem-
onstrated that hepatic telomere length was shortened in cirrhosis
irrespective of the primary disease aetiology and suggested that
the shortening was restricted to hepatocytes. Using a ﬂuores-
cence in situ hybridisation method, they demonstrated telomere
shortening and senescence-associated b-galactosidase (SA-bGAL)
expression in hepatocytes but not in stellate cells or intrahepatic
lymphocytes [61]. Sekoguchi et al. conﬁrmed the negative associ-
ation between hepatic ﬁbrosis and telomere length in liver biopsy
specimens from HCV-infected subjects utilising in situ hybridisa-
tion to conﬁrm the relationship in hepatocytes [75]. Further, they
demonstrated a signiﬁcant association between the rate of telo-
mere shortening and the rate of ﬁbrosis progression.
Ikeda et al. found that large cell change, frequently found in
liver biopsy specimens from older subjects (Fig. 2D), represented
senescent hepatocytes in a study of human liver tissue from
patients with chronic viral hepatitis [76]. SA-bGAL and other
markers associated with senescence such as p21 were expressed
strongly in areas of large cell change.
Rudolph et al. demonstrated the importance of the telomere
system in chronic liver disease in a mouse model; shortened
hepatocyte telomeres induced through telomerase knockout
were associated with an accelerated onset of cirrhosis in the con-
text of chronic liver injury induced with carbon tetrachloride
[77]. Reintroduction of telomerase activity with an adenoviral
vector prevented critical telomere shortening, the onset of cirrho-
sis and deterioration of liver function [77].
Similarly, Wiemann et al. utilised a late generation telomerase
knockout model to demonstrate that mice with short hepatocyte
telomeres had decreased survival when subjected to chronic liver
injury [78]; mice with short telomeres (induced through telome-
rase knockout) and chronic liver damage (induced by hepatocyte
speciﬁc expression of HBV surface antigen under an albumin pro-
moter) had reduced survival when compared to litter-mates with
longer telomeres [78]. Notably however, mice with short telo-
meres showed strong inhibition of HCC formation emphasising
the dual role of telomere shortening.The role of p53 in healthy ageing and cancer
An age-related induction of replicative senescence at the cellular
level, mediated by the telomere system, may be the price of con-
tinued tumour suppression for the whole organism [79,80]. In
mice, driven to senescence by induction of critically short telo-
meres in a telomerase knockout model [81], dysfunction of multi-
ple organs develops with impairment of tissues requiring high
levels of cell replication such as skin, bone marrow, and repro-
ductive organs [81]. Cells demonstrated impaired proliferation
and increased rates of apoptosis but interestingly animals did
not accumulate senescent cells [52]. However, cells from these
mice demonstrated multiple features of telomere-dysfunction
with aneuploidy, chromosomal end-to-end fusions, and high
p53 expression.
These features of cellular and organ senescence can be
reversed through a subsequent lesion of p53, thereby preventing
telomere dysfunction to signal through to cell-cycle arrest, allow-
ing further in vitro cell division and in vivo preservation of organJournal of Hepatology 201function [82]. Telomere shortening in the telomerase deﬁcient
mouse line was associated with increased expression of p53,
growth arrest, and increased apoptosis. Simultaneous lesions of
telomerase and p53 prevented testicular atrophy and cells had
reduced levels of apoptosis with higher rates of passage through
the cell cycle [82]. However, other studies studying organ speciﬁc
deletion of p53 in the context of telomerase-deﬁcient mice, sug-
gest that intestine-speciﬁc loss of p53 allows the persistence of
cells with chromosome instability. These cells gave rise to apop-
tosis-prone intestinal epithelium and therefore premature intes-
tinal failure [83].
However, while these mice have a partial reversal of their
aged phenotype, there was an increased risk of in vitro cellular
transformation and in vivo development of skin, breast, and gas-
trointestinal carcinoma [84]. In contrast to telomerase-deﬁcient
mice, compound telomerase and p53 deﬁcient mice have a high
rate of development of epithelial carcinomas which are associ-
ated with complex non-reciprocal translocations as a conse-
quence of loss of telomere protection of chromosomal ends.
Therefore, these data suggest that telomere attrition in tissues
with a high turnover rate leads to the development of a DNA
damage signal through p53 and subsequent senescence before
loss of telomere chromosomal protection can lead to the develop-
ment of carcinogenic genetic translocations [84].
More recent studies on a similar mouse model by Choudury
et al. have shed further light on the downstream mechanisms
of telomere dysfunction [52]. In late generation telomerase-deﬁ-
cient mice, a subsequent lesion of the cell-cycle inhibitor p21
prevented the accelerated ageing phenotype and organ dysfunc-
tion associated with dysfunctional telomeres but did not lead to
an increase in chromosomal instability or increase in tumour for-
mation demonstrated in the p53 deﬁcient mouse. These two
studies suggest that p21 may mediate cellular senescence down-
stream of dysfunctional telomeres and that p53 has a wider role
in tumour suppression and prevention of cellular transformation.
This interpretation has been reinforced by a study by Xue
et al. [85]. They utilised a tetracycline responsive siRNA to repress
p53 in a mouse model of hepatoblastoma [85]. Re-expression of
p53 led to rapid involution of the tumours due to the develop-
ment of cellular senescence rather than apoptosis. Further, they
demonstrated that the innate immune system was important in
the clearance of senescent cells; antibody or toxin mediated sup-
pression of neutrophil, macrophage or NK cell function prevented
tumour regression [85].Telomeres in HCC
Intact telomere signalling has also been demonstrated to be
important in the development of hepatocellular carcinoma
(HCC). Kojima et al. demonstrated that around 85% of human
HCC specimens show reactivation of telomerase activity [86],
providing a selection advantage aiding uncontrolled hepatocyte
replication.
The beneﬁcial effects of the intact telomere/telomerase sys-
tem have been demonstrated with suppression of the develop-
ment of HCC in a mouse model [78]. Utilising a telomerase
knock-out mouse model, Wiemann et al. demonstrated that short
hepatocyte telomeres were associated with marked inhibition of
HCC formation in a late generation telomerase knock-out mouse
model [78]. Similarly Lechel et al. demonstrated that telomerase0 vol. 53 j 950–961 955
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knockout was associated with HCC suppression in a mouse model
of chronic liver injury [87]. The development of spontaneous rep-
licative senescence in HCC-derived Huh7 cells is associated with
repression of telomerase, telomere shortening, and cell-cycle
arrest [88].
Kim et al. investigated the role of telomere length changes and
downstream telomere signalling in dysplasia and neoplasia in
liver biopsies from chronic hepatitis B virus infected subjects
[89]. With progression from normal hepatocytes through large
cell change, small cell change, and then neoplasia there was a
progressive decline in hepatocyte telomere length measured by
in situ hybridisation and evidence of downstream activation of
the double-strand DNA break pathway with increased phosphor-
ylation of H2AX [89]. Telomeres within HCC were shorter than
surrounding non-cancerous liver [90], suggesting that HCC had
escaped the DNA damage response and subsequent cell-cycle
arrest signal generated from short telomeres. Other studies of
HBV-associated HCC have demonstrated longer telomeres and
higher telomerase activity in hepatocytes from HCC and that
these features correlate with a worse prognosis [91]. Oh et al.
demonstrated increasing transcriptional expression of shelterin
components from normal to dysplastic to neoplastic hepatocytes
in human liver [92]. Further, they demonstrated declining telo-
mere lengths with neoplastic hepatocytes having the shortest
telomere length. Lee et al. have extended these ﬁnding in HBV-
associated carcinogenesis identifying an increase in micronuclei
formation, p21 inactivation and reduction in telomere length
from low grade dysplastic nodules to high grade dysplastic nod-
ules to HCC [93].
Interestingly, short telomeres or telomere dysfunction
appears permissive for the development of early stage neopla-
sia, but inhibitory to later stage and more anaplastic lesions
[94].
The role of the telomere/telomerase system in the pathogen-
esis of HCC have led some to suggest that therapeutic manipula-
tion may hold the promise for future therapies [63]. Telomerase
inhibitors are currently in phase II clinical trials and would repre-
sent a rational therapy for HCC. However, the potential for induc-
ing fatal liver failure, given the results from mouse models, may
limit their safety and efﬁcacy.Oxidative stress
Senescence can occur with oxidative stress or DNA damage dis-
tant to the telomere [43,95]. Zhang et al. [96] compared hepato-
cyte injury in response to hypothermic challenge, leading to
increased oxidative stress, in young and old rats and concluded
that old rats were more susceptible. There is evidence for both a
decline in DNA repair and an increase in DNA or cell sensitivity
to oxidative stress with increasing age. Intano [97] reported a
50% age-related decline in DNA base excision repair in old
age; Hamilton [98] attributed the increased levels of oxidative
damage suffered by DNA in senescent mice and rat livers to
increased DNA or cell sensitivity to oxidative stress. How cell
sensitivity to oxidative stress is mediated is unclear. This may
be mediated by NF-rB [99] which has increased activity with
ageing and which may induce target genes including haemoxy-
genase. Up-regulation of pro-apoptotic genes, such as Gadd153,
which increase cellular sensitivity to oxidative stress, may also
play a role [100].956 Journal of Hepatology 201Oxidative stress and telomeres
Recent evidence suggests that oxidative stress accelerates telo-
mere shortening [101,102]. It has long been known that low
ambient oxygen conditions can extend the lifespan of cells in
culture [103]; however the underlying mechanism of this effect
was uncertain. Studies have demonstrated that when cultured
cells are protected from oxidative stress through low ambient
oxygen tension, addition of anti-oxidants or over-expression
of antioxidant enzymes, telomere shortening is slowed [104–
106].
Telomeres are highly susceptible to oxidative-induced-DNA
damage because of their high guanine content [107]; a human
telomere sequence inserted into a plasmid suffered seven times
more DNA damage due to hydrogen peroxide-induced oxidative
damage than a control DNA sequence [108]. Reactive oxygen spe-
cies cause single-strand DNA breaks and telomeres lack the sur-
veillance mechanisms for single-strand breaks that are
employed in the rest of the genetic material [109]. Induced sin-
gle-strand breaks in non-telomere DNA were repaired within
one day, whereas DNA repair within the telomere was delayed
and ultimately incomplete [109]. The mechanism linking accu-
mulation of oxidative DNA damage and accelerated telomere
shortening is uncertain [101]. One possibility is the extrusion of
telomerase from the nucleus of cells undergoing oxidative stress,
thus preventing the usual intra-nuclear role of telomere preser-
vation. Once in the cytoplasm, telomerase co-localises with mito-
chondria [110]. In cells with over-expression of telomerase,
mitochondrial DNA is protected from oxidative damage and cel-
lular levels of reactive oxygen species are lower than control cells
[110].
Further data has demonstrated the important interaction
between telomere-induced senescence and oxidative stress. Pas-
sos et al. demonstrated that cells driven to either irradiation- or
telomere-induced senescence developed increased mitochondrial
ROS production [111]. Further, they demonstrated that knock-
down of either p53 or p21 prior to induction of senescence pre-
vented the increased mitochondrial ROS production. They
demonstrated that activation of p21, or downstream signalling
through TGF-b, was able to induce further DNA damage foci
and the subsequent DNA damage response, leading to the conclu-
sion of a positive feedback loop [111]. Senescence leads to the
development of oxidative stress which reinforces the senescent
state of the cell and causes further oxidative stress.
Whether the combination of telomere shortening and oxida-
tive stress represents the double hit required to accelerate
progression of liver diseases is uncertain. Certainly the combina-
tion of two concurrent liver diseases leads to accelerated disease
progression and a worse outcome. For example, both diabetes
mellitus (DM) and alcohol misuse accelerate ﬁbrosis progression
in chronic HCV infection [5,30,112,113]. It has been described
that HCV is associated with shortened intrahepatic telomeres
[61] and both DM [114] and alcohol [115] are known to cause
oxidative stress through mitochondrial dysfunction. In their
study of hepatocyte telomeres Sekoguchi et al. investigated the
relationship between hepatocyte telomeres, markers of cell-
turnover and oxidative stress in chronic HCV-infected patients
[75]. They found that hepatocyte telomeres shortened progres-
sively with increasing hepatocyte ﬁbrosis stage and with increas-
ing evidence of hepatocyte oxidative stress as measured by 8
deoxy-guanosine [75].0 vol. 53 j 950–961
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Viruses and the telomere/telomerase system
A number of viruses causing human disease have evolved mech-
anisms for manipulating telomere signalling or telomerase to
promote replication and transmission [116]. EBV and HPV encode
proteins that up-regulate telomerase activity, which may play a
role in the human cancers associated with these viruses.
HBV is associated with a high incidence of HCC. Several
groups have reported a role of HBV genome integration and
up-regulation of telomerase activity. In particular the HBV X
protein disrupts p53 signalling as well as other cellular signal-
ling pathways including protein kinase C and NF-kappa B
[117]. Several groups have demonstrated a direct role of HBV
X protein in the up-regulation of telomerase activity
[118,119]. Others have demonstrated that other HBV associated
proteins also up-regulate telomerase activity [120]. This ability
to bypass functional telomere control of replication might pre-
dispose to HCC formation. However, some groups have demon-
strated suppression of telomerase activity [121]. Recent data
have demonstrated a similar effect of HCV proteins upon telo-
merase activity. Zhu et al. demonstrated a twofold increase in
telomerase activity in Huh7 cells expressing HCV core protein
compared to mock transfected cells [122]. There were detect-
able increases in telomerase mRNA, protein, and promoter activ-
ity; these changes were associated with signiﬁcantly longer
telomere length in cells expressing HCV core, suggesting func-
tional telomerase activity.
Downstream signalling from short telomeres can lead ulti-
mately to cell-cycle arrest. Recent data suggest that cell-cycle
arrest may be advantageous to different viruses. In a p53-knock-
out ﬁbroblast line, CMV replication was noted to be signiﬁcantly
less efﬁcient when p53 was not present [123], suggesting that
some viruses induce a state of cell-cycle arrest to aid replication
and spread. This effect has also been demonstrated for hepatitis B
virus replication. Huang et al. demonstrated that four differing
methods of inducing cell-cycle arrest in the host cell line all led
to increased HBV replication [124]. Induction of G1 cell-cycle
arrest in HepG2 cells led to a reduction in telomerase activity,
but a dramatic increase in HBV replication as measured by HBV
DNA, HBsAg, and HBeAg in culture supernatants [124].
Tarakanova et al. have demonstrated that murine gamma-her-
pes virus can subvert the double-strand DNA break pathway to
promote viral replication [125]. A virus expressed kinase
(orf36) and the homologous EBV kinase (BGLF4) induced phos-
phorylation of H2AX, leading to both replicative arrest of the host
cell and enhanced viral replication. Herpes viral loads were three
logs lower when mice were infected with an orf36-mutated virus
when compared to wild type virus [125].Bypassing the telomere system?
Whether all cell types are affected equally by telomere shorten-
ing and telomerase activity is not known. Data from the mouse
suggested that hepatocytes may bypass the growth inhibitory
effects of short or dysfunctional telomeres in certain circum-
stances [126]. Denchi et al., using a conditional knockout of
TRF2 in hepatocytes, demonstrated evidence of telomere dys-
function with telomere fusions and increased c-H2AX expression.
However, despite telomere dysfunction, there was no increase in
p53 expression and no reduction in hepatic regeneration follow-Journal of Hepatology 201ing partial hepatectomy, but cell replication did not occur.
Instead, the liver was reconstituted by an increase in the size
and ploidy of the remaining hepatocytes [126]. Whether similar
mechanisms operate within the human liver is unknown. Other
groups have demonstrated that human hepatocyte replication
is limited by telomere shortening [127].Other markers in senescence
The presence of senescence can be inferred by other markers. In
particular senescence associated b-galactosidase (SA-bGAL) is
associated with replicative senescence. In a study of liver tissue
from subjects with chronic HCV infection, the presence of SA-
bGAL positive cells was associated with increasing age and
increasing levels of ﬁbrosis [128]. Further, analysing the role of
senescent cells in donor allografts has demonstrated a signiﬁcant
relationship between SA-bGAL positive cells on the reperfusion
biopsy and the subsequent rate of ﬁbrosis progression of post-
transplant HCV recurrence [129].Senescence of other cell types within the liver
The evidence that hepatocytes may be more resistant to the
effects of replicative ageing and telomere shortening is intriguing
[126]. The evidence linking chronic liver disease with telomere
shortening and the rescue of experimentally induced cirrhosis
by telomerase gene delivery [77] generates the possibility that
senescence affects cell types within the liver other than
hepatocytes.
A recent study by Krizhanovsky et al. demonstrated the cru-
cial role of stellate cell senescence in hepatic ﬁbrosis progression
in a murine model subjected to CCl4-induced liver injury [130];
there was accumulation of stellate cells bearing markers of senes-
cence such as SA-bGAL, with a reduced capacity to synthesise
extracellular matrix components. In mice with knockouts of
senescence-associated genes, stellate cells failed to develop
senescence and therefore developed enhanced hepatic ﬁbrosis.
It is perhaps counter-intuitive to ﬁnd that ﬁbrosis progression
was associated with a failure of stellate cells to undergo senes-
cence when cirrhosis is associated with hepatocyte senescence.
Previous human studies have highlighted hepatocyte rather than
stellate cell senescence in the context of chronic liver injury so
the relevance of this model to human cirrhosis must be
questioned.
Sasaki et al. investigated the role of telomere length changes
in biliary epithelium in Primary Biliary Cirrhosis (PBC) [131].
Chronic liver disease relates to chronic inﬂammation of bile
ducts. They demonstrated short telomeres, increased SA-bGAL,
c-H2AX, and increased expression of p16 and p21 in biliary epi-
thelial cells from subjects with PBC [131].
Our group has recently published data examining the associ-
ation between changes in lymphocyte telomere length and clini-
cal outcomes in chronic HCV infection [132]. Subjects with
shorter telomere length in the general CD4+ T-lymphocyte popu-
lation had higher ﬁbrosis stage, poorer survival, and reduced like-
lihood of responding to anti-viral therapies [132].
The precise interplay of differential ageing of various intrahe-
patic cell types in different hepatic diseases may be far more
complex than ﬁrst imagined.0 vol. 53 j 950–961 957
Review
Form and function of senescent cells
There is an increasing body of work demonstrating the role of
senescence in vivo. With the onset of cellular senescence cells
can remain viable within tissues for long periods; resistance to
apoptosis is a characteristic of senescent cells [41,128]. These
cells have a signiﬁcant change in their form and function.
Induction of senescence of ﬁbroblasts in vitro leads to a
change to larger, ﬂatter cells with increasing irregularity of shape
[4]. An increasing body of work describes the change in the cellu-
lar secretosome. This senescence-associated secretory phenotype
(SASP) has been demonstrated in other systems to be pro-inﬂam-
matory (Fig. 7). Kuilman et al. demonstrated that senescent cells
secrete large quantities of IL-6 among other factors such as IL-8
[133]. They demonstrated that IL-6 acted in a paracrine manner
to cause other cells to develop senescence. Depletion of IL-6 pre-
vented this ‘infectious senescence’ [133].
This raises the possibility that once hepatocyte senescence
develops, the change in the tissue micro-environment wrought
by the SASP could lead to other hepatocytes becoming senescent
in a positive feedback loop.Senescence and the liver – potential therapeutic options
The conﬂuence of senescence, oxidative stress, ageing, and ﬁbro-
sis progression suggests possible mechanisms by which ﬁbrogen-
esis and clinical outcome may be manipulated. Avoidance of
factors which are associated with oxidative stress and telomere
dysfunction should be recommended in line with current hepa-
tology practice, which include recommendations to limit alcohol
intake [115], control blood glucose [114], stop smoking, and
reduce weight [57,58].
Future interventions to manipulate telomere length or func-
tion and downstream p53 signalling in ageing and cancer will
require careful study. If we adopt a strategy to attempt to elon-
gate telomeres, by for example inducing telomerase activity to
improve hepatocyte proliferation and thence liver function in
chronic liver disease, there is a substantial risk of cellular trans-











Fig. 7. Senescent cells develop the senescent-associated secretory phenotype
(SASP). Senescent cells secrete large quantities of IL-6, IL-8, and plasminogen
activator inhibitor-1 [133,137]. These can act in both an autocrine or paracrine
manner to reinforce or induce senescence within cells. IL-6 acting via IL-6R/GP80
[133] or IL-8 acting via CXCR2 [137] act in concert with oncogenic stress to induce
the senescent phenotype. ROS, reactive oxygen species.
958 Journal of Hepatology 201of telomerase could have several effects. In cells with pre-existing
damage to cell cycle check-points telomerase activity could be
permissive of unchecked replication, full cellular transformation,
and oncogenesis. However, in cells with intact cell cycle check-
points, elongation, and stabilisation of telomeres could reduce
selection pressure for outgrowth of mutant hepatocyte clones
with damaged check-points, ultimately reducing cancer
carcinogenesis.
However, on the other hand, utilising telomerase inhibition
therapy in the context of HCC [134,135] runs the risk of impairing
remaining hepatocyte proliferative ability and possibly leading to
hepatic decompensation. Wiemann et al. demonstrated in late
generation telomerase knockout mice that short telomeres
strongly inhibited HCC formation, but survival was reduced due
to impairment of hepatocyte regeneration [78].
However, early studies using small molecule inhibitors or RNA
interference have demonstrated that telomerase inhibition may
be a useful therapeutic strategy in the context of HCC
[134,135]. Further, as we discover that telomerase has more
activities than simply elongating telomeres [110], can we deploy
therapeutics which may impair the cellular defences against oxi-
dative damage in the context of pro-oxidant diseases such as
hepatitis C- or alcohol-related liver disease?Conﬂict of interest
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